大麻素受体1阻断剂在治疗肥胖症中的作用

中国临床药理学与治疗学 ›› 2006, Vol. 11 ›› Issue (6): 606-609.

大麻素受体1阻断剂在治疗肥胖症中的作用

庞小翼, 董志, 傅洁民¹

重庆医科大学药学院药理学教研室, 重庆 400016;
¹上海复星医药集团股份有限公司, 上海 200010

收稿日期:2006-03-17 修回日期:2006-04-26 出版日期:2006-06-26 发布日期:2020-12-04
通讯作者: 董志,男,博士,教授,博士导师,主要从事神经药理和中药药理的研究。Tel:023-68486678 E-mail:zhidong073@hotmail.com
作者简介:庞小翼,女,硕士在读,主要从事减肥药物的研究。Tel:023-38733656 E-mail:pxy-2002@163.com

Advances in cannabinoid receptor 1 antagonistic effect in obesity

PANG Xiao-yi, DONG Zhi, FU Jie-min¹

College of Pharmacy, Chongqing University of Medical Sciences, Chongqing 400016, China;
¹FOSUN Pharmaceuticals (Group) Corporaiton, Shanghai 200010, China

Received:2006-03-17 Revised:2006-04-26 Online:2006-06-26 Published:2020-12-04

摘要/Abstract

摘要： 肥胖症已成为世界范围内的流行病, 严重危害着人类健康。目前研究已经证实大麻素受体1(cannabinoid receptor1, CB1-R) 与其发生发展有着密切的关系。CB1-R 属于G 蛋白偶联受体, 其分布和基因结构已经明确。近年来发现CB1-R 阻断剂能通过中枢和外周两种途经降低体重, 调节能量代谢过程, 同时还对乙醇、香烟及药物成瘾有帮助;目前利莫那班(rimonabant, SR141716) 已经进入III 期临床试验, 能有效地降低体重, 且无明显不良反应。CB1-R 阻断剂有望为肥胖症的治疗带来新的曙光。

关键词: 大麻素受体1, 肥胖, 减肥作用, 药物成瘾

Abstract: Obesity which is harmful to human health has become epidemic all over the world.Nowadays, it is reported that cannabinoid receptor 1(CB1-R) is significantly associated with obesity.CB1-R belongs to g-protein coupled receptors(GPCRs).Its distribution and genetic structure have been identefied.Recently it is reported that CB1-R antagonist can regulate energy metabolism and reduce body weight through central and peripherial gateways.Meanwhile, it is helpful in treating alcohol, tobacco and drug addiction.At present, rimonabant (SR141716) has already been applied to phase III clinical trial and it can effectively reduce body weight without causing serious adverse effects.Therefore, CB1-R antagonist can be a better choice for treating obesity in the near future.

Key words: cannabinoid receptor 1, obesity, antiobesity action, drug addiction

中图分类号:

庞小翼, 董志, 傅洁民. 大麻素受体1阻断剂在治疗肥胖症中的作用[J]. 中国临床药理学与治疗学, 2006, 11(6): 606-609.

PANG Xiao-yi, DONG Zhi, FU Jie-min. Advances in cannabinoid receptor 1 antagonistic effect in obesity[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(6): 606-609.

参考文献

1 Rodriguez de Fonseca F, Del Arco I, Bermudez-Silva FJ, Bilbao A, Cippitelli A, Navarro M.The endocannabinoid system:physiology and pharmacology[J].Alcohol Alcohol, 2005;40:2-14
2 Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ.Cannabinoid physiology and pharmacology:30 years of progress[J].Neuropharmacology, 2004;47:345-58
3 Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG. Central nervous system control of food intake[J].Nature, 2000; 404:661-71
4 Park B, Gibbons HM, Mitchell MD, Glassa M.Identification of the CB1 cannabinoid receptor and fatty acid amide hydrolase (FAAH) in the human placenta[J].Placenta, 2003;24:473-8
5 邹大进, 王淼.CB1-R 在治疗代谢综合症中的作用[J].世界临床药物, 2005;26:360-3
6 ElphickMR, Egertova M.The neurobiology and evolution of cannabinoid signalling[J].Philos Trans R Soc Lond B Biol Sci, 2001;356:381-408
7 Labib M.The investigation and management of obesity [J].J Clin Plthol, 2003;56:17-25
8 Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, le Fur G, Oury-Donat F, et al.The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of bbese fa fa rats and in cultured adipocyte cells[J].Mol Pharmacol, 2003;63:908-14
9 Tucci SA, Rogers EK, Korbonits M, Kirkham TC.The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin[J].Br J Pharmacol, 2004; 143:520-3
10 Verty AN, SinghME, McGregor IS, Mallet PE.The cannabinoid receptor antagonist SR141716 attenuates overfeeding induced by systemic or intracranial morphine [J].Psychopharmacology, 2003;168:314-23
11 Tzavara ET, Perry KW, Rodriguez DE, Bymaster FP, Nomikos GG.The cannabinoid CB1 receptor antagonist SR141716A increases norepinephrine outflow in the rat anterior hypothalamus [J].Eur J Pharmacol, 2001;426:R3-4
12 Poirier B, Bidouard JP, Cadrouvele C, Marmiquet X, Staels B, O'Connor SE, et al.The anti-obesity effect of rimonabant is associated with an improved serum lipid profile[J].Diabetes Obes Metab, 2005;7:65-72
13 Liu YL, Connoley IP, Wilson CA, Stock MJ.Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep (ob) Lep (ob) mice[J].Int J Obes (Lond), 2005;29:183-7
14 Pertwee RG.Cannabinoids and the gastrointestinal tract[J]. Gut, 2001;48:859-67
15 Storr M, Sibaev A, Marsicano G, Lutz B, Schusdziarra V, Timmermans JP, et al.Cannabinoid receptor type 1 modulates excitatory and inhibitory neurotransmission in mouse colon[J].Mol Pharmacol, 2003;63:908-14
16 Carai MA, Colombo G, Gessa GL.Rapid tolerance to the intestinal prokinetic effect of cannabinoid CB1 receptor antagonist, SR141716(Rimonabant) [J].Eur J Pharmacol, 2004;494:221-4
17 Jbilo O, Ravinet-Trillou C, Arnone M, Buisson I, Bribes E, Peleraux A, et al.The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance[J].FASEB J, 2005;19:1567-9
18 Weyer C, Funahashit, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al.Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia [J].J Clin Endocrinol Metab, 2001;86:1930-5
19 Carai MA, Colombo G, Gessa GL.Rimonabant:the first therapeutically relevant cannbinoid antagonist[J].Life Sci, 2005; 23;77:2339-50
20 Beardsley PM, Thomas BF.Current evidence supporting a role of cannabinoid CB1 receptor (CB1R) antagonists as potential pharmacotherapies for drug abuse disorders[J].Behav Pharmacol, 2005;16:275-96
21 Daniela C, Stephen CW.The role of the endocannabinoid system in the regulation of energy homeostasis [J].Current Opinion in Endocrinology &Diabetes, 2005;12:338-51

[1]	郭怡洵, 关晓印, 王博, 魏英达, 张岩, 林建华. 肌少性肥胖的发病机制及潜在治疗靶点研究进展[J]. 中国临床药理学与治疗学, 2023, 28(3): 341-346.
[2]	赵世峰, 宋向明, 姚建平. 新型胰高血糖素样肽-1受体/葡萄糖依赖性促胰岛素多肽受体双重激动剂——Tirzepatide[J]. 中国临床药理学与治疗学, 2023, 28(2): 220-227.
[3]	马怡彤, 马建红, 高亚婷, 刘畅. 脂肪细胞因子在子宫内膜癌中的作用及研究进展[J]. 中国临床药理学与治疗学, 2023, 28(11): 1315-1320.
[4]	孔祥, 华强, 姚新明, 孟祥健, 钟民, 郭莉群. 芝麻酚调控巨噬细胞极化改善肥胖小鼠脂肪组织炎症及胰岛素抵抗[J]. 中国临床药理学与治疗学, 2020, 25(7): 728-733.
[5]	袁李佳龙，秦旭平. ATP合酶β亚基功能与疾病[J]. 中国临床药理学与治疗学, 2018, 23(4): 464-470.
[6]	曾慧，肖兰，易宏辉. HRH1与HRH2受体基因多态性与肥胖以及肥胖相关性状的关联分析[J]. 中国临床药理学与治疗学, 2016, 21(9): 1028-1032.
[7]	黄昭穗，杨骄，黄昭瑄，栾丽丽，王赐玉，杨红英. 利拉鲁肽在血糖控制不佳的T2MD伴肥胖患者中临床疗效观察[J]. 中国临床药理学与治疗学, 2016, 21(1): 87-92.
[8]	沈纪中, 柳航. 高糖饮水诱导代谢综合征小鼠模型的实验研究[J]. 中国临床药理学与治疗学, 2014, 19(9): 1011-1015.
[9]	陈咨苗, 王美荣, 叶婷婷, 顾雪疆, 陈雄, 朱虹, 倪连松. 酮替芬对高糖高脂饮食诱导肥胖模型大鼠的减肥作用[J]. 中国临床药理学与治疗学, 2014, 19(1): 23-28.
[10]	刘靖, 孙宁玲, 杨松娜, 马志毅, 杨靓. 奥利司他对肥胖高血压患者非内皮依赖性血管舒张功能的影响[J]. 中国临床药理学与治疗学, 2009, 14(9): 1061-1064.
[11]	巫冠中, 郭永起, 苏欣, 杨红霞, 章娟. 大豆黄素衍生物LRXH609 的减肥作用及机理探讨[J]. 中国临床药理学与治疗学, 2009, 14(5): 519-523.
[12]	崔明霞, 王磊, 张宝来, 路莉, 王莉, 郑荣梁, 吴勇杰. 糖尿病性肥胖大鼠模型的建立及西布曲明对其治疗作用的研究[J]. 中国临床药理学与治疗学, 2008, 13(12): 1325-1329.
[13]	陈光亮, 李莉, 严尚学, 黄德武. 盐酸西布曲明对营养性肥胖大鼠的减肥作用[J]. 中国临床药理学与治疗学, 2003, 8(1): 55-58.
[14]	王绘, 陈斌. 西布曲明对不同肥胖者的减重作用[J]. 中国临床药理学与治疗学, 2002, 7(4): 327-330.
[15]	王平芳, 杨雅, 廖二元, 颜湘, 张红, 何凌, 朱旭平. 西布曲明对肥胖伴糖脂代谢异常的治疗作用[J]. 中国临床药理学与治疗学, 2002, 7(3): 224-230.